European Archives of Oto-Rhino-Laryngology

, Volume 254, Supplement 1, pp S105–S109 | Cite as

Positive impact of retinyl palmitate in leukoplakia of the larynx

  • W. J. Issing
  • R. Struck
  • A. Naumann
Laryngology

Abstract

Laryngeal leukoplakia can be a premalignant precursor of squamous cell carcinoma, is often tobacco-related and can usually be readily monitored by indirect laryngoscopy. One of the main motivations for using retinyl palmitate in patients with persistent leukoplakia was to avoid general anesthesia for elderly patients, who are considered to be high-risk patients when direct larynoscopy is required for possible tissue biopsy. Our study was the first to investigate the effectiveness and toxicity of high-dose retinyl palmitate in the treatment of laryngeal leukoplakia. Treatment was divided into two phases. In the first phase, all patients underwent induction therapy with 300,000 IU/day of retinyl palmitate for the 1st week, which was then adjusted up to 1,500,000 IU/day in the 5th week in patients with resistant lesions. Patients whose lesions progressed during this period were withdrawn from the study. In the second phase, patients whose lesions responded to treatment or remained stable were assigned to a maintenance therapy of 150,000 IU/day. Complete remission was observed in 15 of 20 patients (75% of cases). Partial response was seen in the remaining 5 patients, with 3 of the patients relapsing. The median duration of treatment and follow-up was 18 months (range, 12–24 months). These results indicate that retinyl palmitate has substantial activity in laryngeal leukoplakias. Since only minor side effects were seen, the medication is an excellent candidate as a preventive agent for laryngeal cancer.

Key words

Larynx Leukoplakia Retinyl palmitate Vitamin A 

References

  1. 1.
    Acheson ED, Cowdell RH, Hadfield E, et al (1968) Nasal cancer in wood workers in the furniture industry. BMJ 2: 587–590PubMedCrossRefGoogle Scholar
  2. 2.
    Ajani JA, Welch SR, Raber MN, et al (1990) Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147–159PubMedGoogle Scholar
  3. 3.
    American Cancer Society (1993) Cancer, facts and figures 1993. ACS, AtlantaGoogle Scholar
  4. 4.
    Benner SE, Hong WK, Lippman SM, et al (1992) Intermediate biomarkers in upper aerodigestive tract and lung chemoprevention trials. J Cell Biochem 16G [Suppl]:33–38CrossRefGoogle Scholar
  5. 5.
    Blomhoff R, Green MH, Berg T, et al (1990) Transport and storage of Vitamin A. Science 250:399–404PubMedGoogle Scholar
  6. 6.
    Boring CC, Squires TS, Tong T (1991) Cancer statistics, 1991. CA 41:19–36PubMedGoogle Scholar
  7. 7.
    Chiesa F, Sala L, Costa L, et al (1986) Excision of oral leukoplakia by carbon dioxide laser on an out-patient basis: a useful procedure for prevention and early detection of oral carcinoma. Tumori 2:307–312Google Scholar
  8. 8.
    Chiesa F, Tradati N, Marazza M, et al (1992) Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Oral Oncol Eur J Cancer 2:97–102CrossRefGoogle Scholar
  9. 9.
    Chu FWK, Silverman S Jr, Dedo HH (1988) Carbon dioxide laser treatment of oral leukoplakia. Laryngoscope 98:125–130PubMedGoogle Scholar
  10. 10.
    De Vries N, Zandwijk N van, Pastorino U (1991) The euroscan study. Br J Cancer 64:985–989PubMedGoogle Scholar
  11. 11.
    Duchon J, Czinger J, Pupp L (1972) Stimmbandpachydermien und das Rauchen. Z Laryngol Rhinol 51:253–255Google Scholar
  12. 12.
    Frame JW, Dasgupta AR, Dalton GA (1984) Use of the carbon dioxide laser in the management of premalignant lesions of the oral mucosa. J Laryngol Otol 98:1251–1260PubMedGoogle Scholar
  13. 13.
    Hong WK, Endicott J, Itri LM, et al (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501–1505PubMedCrossRefGoogle Scholar
  14. 14.
    Hong WK, Lippman SM, Itri LW, et al (1990) Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795–801PubMedCrossRefGoogle Scholar
  15. 15.
    Kelloff GJ, Boone CW, Steele VK, et al (1993) Development of chemopreventive agents for lung and upper aerodigestive tract cancers. J Cell Biochem 17F [Suppl]:2–17Google Scholar
  16. 16.
    Lippman SM, Hong WK (1989) Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17:691–694PubMedGoogle Scholar
  17. 17.
    Lippman SM, Hong WK (1992) 13-cis-retinoic acid and cancer chemoprevention. J Natl Cancer Inst Monogr 13:111–115PubMedGoogle Scholar
  18. 18.
    Lippman SM, Batsakis JG, Toth BB, et al (1993) Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15–20PubMedCrossRefGoogle Scholar
  19. 19.
    Lippman SM, Benner SE, Hong WK (1993) Chemoprevention strategies in lung carcinogenesis. Chest 103: 15S-19SPubMedGoogle Scholar
  20. 20.
    Lotan R, Xu X-C, Lippman SM, et al (1995) Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332:1405–1410PubMedCrossRefGoogle Scholar
  21. 21.
    Maran AGD, Wilson JA, Gaze MN (1993) The nature of the head and neck cancer. Eur Arch Otorhinolaryngol 250: 127–132PubMedCrossRefGoogle Scholar
  22. 22.
    Meyskens FL Jr, Goodman GE, Alberts DS (1985) 13-cisretinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. Crit Rev Oncol Hematol 3:75–101PubMedGoogle Scholar
  23. 23.
    Pastorino U, Infante M, Maioli M, et al (1993) Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216–1222PubMedGoogle Scholar
  24. 24.
    Silverman S Jr, Gorsky M, Lozada F (1984) Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 53:563–568PubMedCrossRefGoogle Scholar
  25. 25.
    Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6:963–968PubMedCrossRefGoogle Scholar
  26. 26.
    Smith MA, Parkinson DR, Cheson BD, et al (1992) Retinoids in cancer therapy. J Clin Oncol 10: 839–864PubMedGoogle Scholar
  27. 27.
    Spom B (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699–2702Google Scholar
  28. 28.
    Stich HF, Hornby AP, Mathew B, et al (1988) Response of oral leukoplakia to the administration of vitamin A. Cancer Lett 40: 93–101PubMedCrossRefGoogle Scholar
  29. 29.
    Stich HF, Rosin MP, Hornby AP, et al (1988) Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 42:195–199PubMedGoogle Scholar
  30. 30.
    Strong MS, Incze J, Vaughan CW (1984) Field cancerization in the aerodigestive tract — its etiology, manifestation, and significance. J Otolaryngol 13:1–6PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • W. J. Issing
    • 1
  • R. Struck
    • 1
  • A. Naumann
    • 1
  1. 1.Department of Otorhinolaryngology, Klinikum GroβhademLudwig-Maximilians-UniversitätMunichGermany

Personalised recommendations